Here are four things to know.
1. The FDA approved Bavencio to treat advanced or metastatic bladder cancer in patients whose disease still progresses after chemotherapy.
2. New York City-based Pfizer developed the drug with Darmstadt, Germany-based Merck. As part of the accelerated approval, the drugmakers must conduct another clinical trial to confirm the drug’s efficacy for this treatment indication.
3. The drug will cost about $13,000 a month for the average bladder cancer patient, according to German Merck.
4. The decision comes just two months after Bavencio received FDA approval to treat a rare form of skin cancer.
More articles on supply chain:
WHO calls for global drug price transparency
Patients barter for costly medications on Facebook
PhRMA issues new membership criteria, boots more than 20 drugmakers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.